Core Viewpoint - Beihai Kangcheng-B (01228) reported a significant decline in revenue for the six months ending June 30, 2025, with earnings of 22.248 million, a decrease of 50.33% year-on-year, while net profit reached 59.238 million, contrasting with a loss of 247 million in the same period last year [1] Financial Performance - The company's revenue decreased primarily due to its strategic focus on rare diseases initiated in 2021, leading to the termination of the distribution agreement for He Li An® by the end of 2024, which halted sales in Taiwan [1] - Excluding the sales of He Li An® in Taiwan, revenue decreased by 1.7 million or 6.9% compared to the same period in 2024, attributed to proactive inventory management and reduced stock of Mai Ruibei® in the channels during the first half of 2025 [1]